UK-based Contract Development Manufacturing Organisation (CDMO) Oxford Biomedica (OXB) may be open to a private equity takeover, provided any offer meets the company's valuation expectations and supports its long-term growth ambitions.
British drugmaker GSK has acquired Nuvalent, a Boston-based clinical-stage biopharmaceutical company focused on precisely targeted oncology therapies, for an equity value of $10.6 billion (~£8 billion).
American private equity firm TA Associates has invested in South Korean medical imaging software company AIRS Medical, backing its AI-driven MRI technology as the company pushes further international expansion. The investment reflects ongoing demand across healthcare systems for ways to increase imaging capacity without adding scanners.
German private equity firm NORD Holding has acquired Munich-based healthcare revenue cycle management (RCM) specialist Medas Group from Liberta Partners, a Munich-headquartered multi-family holding company. Liberta acquired Medas in 2022.
Bosnia and Herzegovina’s largest private integrated healthcare network, ASA Medical Group, has acquired Sarajevo Heart Centre, a Bosnian private provider of advanced cardiac and intensive care.
Germany’s outpatient intensive care market is entering a period of structural change, creating significant opportunities for providers with scale, according to Dr Erik Hamann, CEO of Opseo, a German provider of intensive care services. HBI recently spoke to Hamann about Germany’s hospital reform, increasing regulatory complexity and ongoing market consolidation. These trends are reshaping the […]
Healthcare-focused private equity firm ARCHIMED has acquired Barcelona-based Institut de Radiofarmàcia Aplicada de Barcelona (IRAB), a developer, manufacturer and supplier of PET radiopharmaceuticals used in medical imaging, clinical trials and biomedical research.
Huron, a Nasdaq-listed global professional services firm, has acquired AI-enabled clinical and patient access solutions provider RelateCare from private equity firm MML Growth Capital Partners Ireland.
SK Capital Partners, a New York-based investment firm focused on life sciences, speciality materials, and ingredients, has acquired Swiss drug distribution company Swixx BioPharma for €1.5 billion (~US$1.73 bn). Specialised investment firm Bain Capital Life Sciences also joined SK Capital as a minority investor.
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.